Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 10/20 | 0.45 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CALML3 | P27482 | 1/20 | 0.45 |
| ▸ | SDHA | P31040 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14540785 | 1.00 | KCNH2 (0.50) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL14541190 | 0.88 | MAOA (0.49) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5333688 | 0.88 | MAOA (0.49) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5328394 | 0.84 | MAOB (0.47) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL14540983 | 0.84 | MAOB (0.45) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL14541188 | 0.84 | MAOB (0.47) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL14540833 | 0.81 | MAOB (0.55) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL14540827 | 0.80 | MAOB (0.46) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5334630 | 0.79 | MAOB (0.48) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5334612 | 0.79 | MAOB (0.48) | KCNH2MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007040326-A1 | A NOVEL OXAZOLIDINONE FORMAMIDE DERIVATIVE AND PREPARATION METHOD THEROF | ILDONG PHARMACEUTICAL CO., LTD (KR) | 2007-04-12 | — | — | WO | disclosed |